hilarious_marcupial@DESKTOP-KOMPK5V:/mnt/c/Users/dylan/2ndOpinionMD-MVP$ bash scripts/portalnode4090_mkg_harne
ss.sh "First-line therapy for T2DM with CKD considerations"
🚀 Starting MKG retrieval harness
❓ Query ready (51 chars)
🧰 No source filter; searching full pilot slice
📚 Loaded pilot source dictionary (38 keys)
/mnt/c/Users/dylan/2ndOpinionMD-MVP/.venv_embed/lib/python3.12/site-packages/torch/cuda/__init__.py:180: UserW
arning: CUDA initialization: The NVIDIA driver on your system is too old (found version 12060). Please update
your GPU driver by downloading and installing a new version from the URL: http://www.nvidia.com/Download/index
.aspx Alternatively, go to: https://pytorch.org to install a PyTorch version that has been compiled with your
version of the CUDA driver. (Triggered internally at /pytorch/c10/cuda/CUDAFunctions.cpp:119.)
  return torch._C._cuda_getDeviceCount() > 0
🧠 Loading embedding model=BAAI/bge-base-en-v1.5 on device=cpu
Warning: You are sending unauthenticated requests to the HF Hub. Please set a HF_TOKEN to enable higher rate l
imits and faster downloads.
Loading weights: 100%|████████████████████████████████████████████████████| 199/199 [00:00<00:00, 2395.83it/s]
📐 Embedding query (51 chars)
✅ Query embedding complete in 74.0249s
🔐 Using database URL from SYNC_DATABASE_URL
🗄️ Running semantic + TS retrieval (top_k=10)
📊 DB retrieval done in 2.2230s (semantic=10 ts=0)
🔀 Overlap computed (both=0 jaccard=0.000)
🧪 Running Ollama synthesis pass
🧾 Preparing retrieval bundle for LLM analysis
⚠️ LLM synthesis failed: No module named 'requests'
📦 Emitting JSON output (11911 chars)
{
  "query": "First-line therapy for T2DM with CKD considerations",
  "top_k": 10,
  "sources_filter": null,
  "embed_model": "BAAI/bge-base-en-v1.5",
  "pilot_slice_source_reference": {
    "rxnorm": "NLM RxNorm drug and ingredient concepts (RxCUI, names, TTYs).",
    "loinc": "LOINC laboratory and clinical observation codes with long names.",
    "hpo": "Human Phenotype Ontology terms (phenotypes, disease manifestations).",
    "snomed": "SNOMED CT clinical concepts (disorders, findings, procedures).",
    "icd10cm": "ICD-10-CM diagnosis codes and official long titles (US clinical modification).",
    "icd11": "WHO ICD-11 foundation mortality and morbidity content mirrored for search.",
    "orphanet": "Orphanet rare disease names, synonyms, and classification text.",
    "chv": "Consumer Health Vocabulary \u2014 lay-language terms linked to clinical concepts (UMLS CHV).",
    "va_guidelines": "VA/DoD clinical practice guideline sections ingested as rag_corpus chunks.",
    "acc_aha_valvular_2020": "2020 ACC/AHA guideline on valvular heart disease (chunked text).",
    "ada_dm_2024": "American Diabetes Association Standards of Care (diabetes mellitus, 2024 vintage).",
    "kdigo_ckd_2021": "KDIGO 2021 clinical practice guideline for chronic kidney disease (CKD).",
    "kdigo_ckd_2024": "KDIGO 2024 CKD evaluation and management guideline excerpts.",
    "kdigo_gn_ln_2021": "KDIGO 2021 guideline for glomerular diseases including lupus nephritis.",
    "kdigo_anemia_ckd_2023": "KDIGO 2023 clinical practice guideline for anemia in CKD.",
    "gold_copd_2023": "GOLD 2023 Global Strategy for Diagnosis, Management, and Prevention of COPD.",
    "gold_copd_2024": "GOLD 2024 COPD strategy document excerpts.",
    "gina_asthma_2023": "GINA 2023 Global Strategy for Asthma Management and Prevention.",
    "cdc_opioid": "CDC opioid prescribing guideline narrative sections (structured plain text).",
    "acr_eular": "Joint ACR/EULAR classification or criteria publications (combined tag).",
    "acr_ild_2023": "ACR guidance on idiopathic inflammatory myopathies with ILD (2023).",
    "acr_ra_2021": "ACR guideline or guidance on rheumatoid arthritis management (2021).",
    "acr_npf_psa_2018": "ACR/NPF joint guideline on psoriasis and psoriatic arthritis (2018).",
    "acr_vf_anca_2021": "ACR/VF guideline on ANCA-associated vasculitis (2021).",
    "acr_reproductive_health_2020": "ACR reproductive health guidance for rheumatic disease (2020).",
    "eular_acr_sle_2019": "EULAR/ACR classification criteria or lupus management collaboration (2019).",
    "eular_ra_2022": "EULAR recommendations for rheumatoid arthritis management (2022).",
    "eular_psa_2020": "EULAR recommendations for psoriatic arthritis pharmacologic therapy (2020).",
    "eular_sle_nephritis_2025": "EULAR recommendations on management of lupus nephritis (2025).",
    "eular_anca_2022": "EULAR recommendations for ANCA-associated vasculitis (2022).",
    "eular_lvv_2018": "EULAR recommendations for large-vessel vasculitis (2018).",
    "eular_axspa_2022": "EULAR recommendations for axial spondyloarthritis (2022).",
    "asas_eular_axspa_2022": "ASAS\u2013EULAR recommendations for axial spondyloarthritis (2022).",
    "diagrules": "Curated diagnostic-rule narrative cards used as RAG chunks.",
    "eoh_canon_v6": "Ethos of Health canon v6 narrative chunks (foundational clinical ethos text).",
    "eoh_2025": "Ethos of Health 2025 corpus excerpts in rag_corpus.",
    "eoh_gold_2025": "Ethos of Health \u00d7 GOLD COPD 2025 cross-reference or summary chunks.",
    "ethos_model": "Short Ethos-of-Health model or meta documents (small row count)."
  },
  "embed_device": "cpu",
  "embed_sec": 74.0249,
  "db_sec": 2.223,
  "semantic_hits": [
    {
      "id": 11243205,
      "source": "kdigo_ckd_2024",
      "source_id": "kdigo_ckd_2024:p0102",
      "title": "KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Dis
ease \u2013 page 102",
      "text": "appears to be irrespective of the level of GFR, with no\nevidence of a threshold level of eGFR
below which ben-\ne\ufb01ts start to attenuate.\nFor the 1A recommendation (3.7.1), also see the 2022\nupdate
to the KDIGO Clinical Practice Guideline in Diabetes\nManagement for details of the certainty of the evidence.
\n23 Our\nERT speci\ufb01cally also undertook a systematic review limited to\npeople with CKD and no diabetes
and considered the\ncertainty of the effect in this subgroup t\u2026[truncated]",
      "score": 0.7774626149259453
    },
    {
      "id": 11243202,
      "source": "kdigo_ckd_2024",
      "source_id": "kdigo_ckd_2024:p0099",
      "title": "KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Dis
ease \u2013 page 99",
      "text": "eGFR <30 ml/min per 1.73 m2, compared with those who\ncontinue.508,509 In addition, a recent in
dividual patient level\ndata meta-analysis demonstrated a bene\ufb01t in delaying KRT\nin patients with eGFR<3
0 ml/min per 1.73 m2.510\n3.7 Sodium-glucose cotransporter-2 inhibitors\n(SGLT2i)\nThe Work Group concurs with
 the KDIGO 2022 Clinical\nPractice Guideline for Diabetes Management in Chronic\nKidney Disease, which stated:
 \u201cWe recommend treating pa-\ntients with type 2 diabetes \u2026[truncated]",
      "score": 0.770134999147953
    },
    {
      "id": 11244308,
      "source": "ada_dm_2024",
      "source_id": "ada_dm_2024:p0200",
      "title": "ADA Standards of Medical Care in Diabetes \u2014 2024 \u2013 page 200",
      "text": "leading to the recommendation that sem-\na g l u t i d ec a nb eu s e da sa n o t h e r\ufb01rs
t-line\nagent for people with CKD (137,138).\nOther GLP-1 RAs (liraglutide and dulaglu-\ntide) may also have C
KD bene\ufb01ts, but no\nother dedicated kidney trials have been\npublished. Similarly, no dedicated kidney\no
utcomes studies for the dual GIP and\nGLP-1 RA (tirzepatide) have been pub-\nlished. Dedicated kidney outcomes
 trials\nin people with CKD and type 2 diabetes\nhave shown that\u2026[truncated]",
      "score": 0.7684191007364346
    },
    {
      "id": 11243206,
      "source": "kdigo_ckd_2024",
      "source_id": "kdigo_ckd_2024:p0103",
      "title": "KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Dis
ease \u2013 page 103",
      "text": "Rationale\nLarge trials individually and when combined in meta-analysis\ndemonstrate clear net
bene\ufb01ts of SGLT2i, with net bene\ufb01ts\nparticularly large in people without diabetes due to almost no\
nrisk of serious harm from ketoacidosis or lower-limb ampu-\ntation.\nRecommendation 3.7.3: We suggest treatin
g adults\nwith eGFR 20 to 45 ml/min per 1.73 m\n2 with urine\nACR <200 mg/g (<20 mg/mmol) with an SGLT2i\n(2B)
.\nThis recommendation places high value on the potential for lo\u2026[truncated]",
      "score": 0.7663325806657936
    },
    {
      "id": 11243204,
      "source": "kdigo_ckd_2024",
      "source_id": "kdigo_ckd_2024:p0101",
      "title": "KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Dis
ease \u2013 page 101",
      "text": "acid levels,515 weight/\ufb02uid overload,516 and the risk of serious\nhyperkalemia.517\nHarms.
 SGLT2i are well tolerated with high levels of\nadherence in the RCTs in CKD. 403,513,514 In the studied\npopu
lations, any risk of ketoacidosis or lower-limb\namputation resulting from SGLT2i use was substantially\nlower
 than the potential absolute bene \ufb01ts and generally\nrestricted to people with diabetes. Meta-analysis es
timates of\nabsolute bene \ufb01ts and harms for each 1000 people \u2026[truncated]",
      "score": 0.7624344371298305
    },
    {
      "id": 11243148,
      "source": "kdigo_ckd_2024",
      "source_id": "kdigo_ckd_2024:p0045",
      "title": "KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Dis
ease \u2013 page 45",
      "text": "Practice Point 3.8.2: A nonsteroidal MRA may be added to a RASi and an SGLT2i for treatment of
T2D and CKD in adults.\nPractice Point 3.8.3: To mitigate risk of hyperkalemia, select people with consistentl
y normal serum potassium concen-\ntration and monitor serum potassium regularly after initiation of a nonstero
idal MRA (Figure 26).\nPractice Point 3.8.4: The choice of a nonsteroidal MRA should prioritize agents with do
cumented kidney or\ncardiovascular bene\ufb01ts.\nPra\u2026[truncated]",
      "score": 0.7582564498033268
    },
    {
      "id": 11244124,
      "source": "ada_dm_2024",
      "source_id": "ada_dm_2024:p0016",
      "title": "ADA Standards of Medical Care in Diabetes \u2014 2024 \u2013 page 16",
      "text": "and worsening of cardiometabolic abnor-\nmalities that often result from sudden\ndiscontinuatio
n of weight management\npharmacotherapy.\nRecommendation 8.25 was revised to\nemphasize use of a CGM device to
 im-\nprove safety in individuals with post\u2013\nmetabolic surgery hypoglycemia.\nUpdated Tables 8.1 and 8.2
 provide\ndetailed information on the ef\ufb01cacy, com-\nmon side effects, safety considerations,\nand costs
of approved weight manage-\nment pharmacotherapy options.\nDiscuss\u2026[truncated]",
      "score": 0.7579607223249033
    },
    {
      "id": 11244318,
      "source": "ada_dm_2024",
      "source_id": "ada_dm_2024:p0210",
      "title": "ADA Standards of Medical Care in Diabetes \u2014 2024 \u2013 page 210",
      "text": "diabetes: a meta-analysis. JAMA Cardiol 2021;6:\n148\u2013158\n140. Reyes-Farias CI, Reategui-D
iaz M, Romani-\nRomani F, Prokop L. The effect of sodium-glucose\ncotransporter 2 inhibitors in patients with
chronic\nkidney disease with or without type 2 diabetes\nmellitus on cardiovascular and renal outcomes: a\nsys
tematic review and meta-analysis. PLoS One\n2023;18:e0295059\n141. Herrington WG, Staplin N, Wanner C, et al.;
\nEmpa-Kidney Collaborative Group. Empagli\ufb02ozin\nin patient\u2026[truncated]",
      "score": 0.7550734573515109
    },
    {
      "id": 11243203,
      "source": "kdigo_ckd_2024",
      "source_id": "kdigo_ckd_2024:p0100",
      "title": "KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Dis
ease \u2013 page 100",
      "text": "without diabetes who are at very low risk of ketoacidosis). SGLT2i\nalso favorably reduce BP, u
ric acid levels, measures of\ufb02uid over-\nload, the risk of serious hyperkalemia, and do not increase risk
of\nhypoglycemia. The recommendation is consistent with but ex-\npands on Recommendation 1.3.1 from theKDIGO 2
022 Clinical\nPractice Guideline for Diabetes Management in Chronic Kid-\nney Diseaseto include people with ca
uses of CKD not related to\ndiabetes.\nKey information\nB\u2026[truncated]",
      "score": 0.7542752398766536
    },
    {
      "id": 11244359,
      "source": "ada_dm_2024",
      "source_id": "ada_dm_2024:p0251",
      "title": "ADA Standards of Medical Care in Diabetes \u2014 2024 \u2013 page 251",
      "text": "activity (92\u201394). Glucagon-like peptide 1\n(GLP-1) receptor agonists (RAs) have\nalso been
 shown to improve kidney out-\ncomes (95\u2013100). Kidney effects should\nbe considered when selecting agents
\nfor glucose lowering (see Section 9,\n\u201cPharmacologic Approaches to Glycemic\nTreatment\u201d).\nSelecti
on of Glucose-Lowering\nMedications for People With Chronic\nKidney Disease\nFor people with type 2 diabetes a
nd es-\ntablished CKD, special considerations for\nthe selection of glucose-\u2026[truncated]",
      "score": 0.7528642640371485
    }
  ],
  "ts_hits": [],
  "overlap": {
    "semantic_only": [
      11243148,
      11243202,
      11243203,
      11243204,
      11243205,
      11243206,
      11244124,
      11244308,
      11244318,
      11244359
    ],
    "ts_only": [],
    "both": [],
    "jaccard": 0.0
  },
  "llm": {
    "error": "No module named 'requests'"
  }
}
🏁 Harness run complete

---

## Meta-commentary (assistant)

- Retrieval quality is directionally strong for this query: semantic hits are dominated by `kdigo_ckd_2024` and `ada_dm_2024`, which is exactly the expected source mix for T2DM+CKD first-line management.
- `ts_hits` is empty while semantic returned 10/10; this suggests lexical mismatch (query phrasing vs `ts` tokens), not corpus absence. Worth testing an expanded lexical seed (e.g., `SGLT2`, `GLP-1`, `eGFR`, `albuminuria`) in follow-up runs.
- Embedding completed on CPU due CUDA initialization warning; runtime was acceptable for one query but will scale poorly in batch. Driver/toolchain update should restore GPU path.
- LLM synthesis failed solely because `requests` is missing in the active venv; retrieval pipeline itself succeeded end-to-end.
- Immediate fix list before full benchmark: `pip install requests`, ensure Ollama endpoint reachable, then rerun with 10-question batch and compare semantic/TS overlap distribution.